DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
Mega JL, Braunwald E, Mohanavelu S. ATLAS ACS-TIMI 46 study group. et al.
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Lancet 2009;
374 (9683): 29-38
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.